Dihexa vs PE-22-28 China Supplier Guide

Keep Dihexa and PE-22-28 specifications separate

Create independent RFQ and purchase-order lines with full controlled names, molecular references, material form, purity target, strength, vial count and RUO status. Do not infer interchangeability from a cognitive or specialty category. Require the supplier to map each internal code to the exact identity and retain that mapping on the COA, analytical sample, label and packing list. Any proposed substitution requires a new technical review and explicit written buyer approval.

Compare overlapping 5mg and 10mg options

Record each product-strength combination separately, including vials, kits, total nominal material, content tolerance, lot, units per box and price basis. Equal 5mg or 10mg labels do not mean equal molecules, methods or supply risks. Ask whether strengths share a parent lot and how finished genealogy is controlled. Compare total documented material and evidence scope rather than ranking offers by vial price, box count or an unsupported headline purity.

Require product-specific HPLC and MS files

Dihexa needs its own identity and purity evidence, and PE-22-28 needs separate batch-linked evidence. Check expected molecular information, sample identifier, chromatogram, integration, method reference, dates, report numbers and authorization. One product's report cannot qualify the other, and a category-level certificate is inadequate. Confirm the tested sample connects to the offered batch and retain original files. Investigate altered images, inconsistent identifiers or unexplained report revisions.

Verify content and prevent mixed-order swaps

Ask which quantitative method or filling record supports every strength and what tolerance applies. A high HPLC purity result does not prove 5mg or 10mg content. Require distinct full-name labels, product codes, lot numbers and secondary packaging. For mixed orders, obtain a segregated packing list and ask how line clearance, picking checks and reconciliation prevent swaps. Receiving staff should sample-check units and quarantine any product, strength or lot inconsistency.

Score the supplier at SKU and lot level

A supplier may control one material well and provide incomplete evidence for another. Score document accuracy, analytical completeness, communication, packaging, fulfillment and corrective response for each product and batch. Clarify released stock, MOQ, lead time and repeat-order continuity independently. Require change notification before a manufacturing site, laboratory, method, fill operation, label or packaging change. Repeat the batch review for every new lot instead of assuming approval transfers across the catalog.

Map accountability before supplier approval

Document the legal seller, manufacturing site, analytical laboratory, filling or packaging site, inventory owner, release authority and dispatch entity for the exact SKU. A supplier may coordinate qualified partners, but the arrangement and responsibilities must be transparent. Ask who retains original records, investigates deviations and authorizes corrections. Require notification before a critical party changes. This map separates technical control from a generic factory claim and identifies who is accountable when a report, label, package or received quantity does not match the approved purchase order.

Build one comparable wholesale quotation matrix

Send every supplier the same fields: exact identity, strength, vial count, total material, target purity, identity method, quantitative-content basis, offered lot, testing status, packaging, documents, lead time and shipping term. Mark missing answers as exceptions rather than filling gaps with assumptions. Separate one-time testing or setup costs from recurring unit costs. This creates one auditable decision record for scientific, purchasing and quality reviewers and prevents the lowest-looking offer from winning simply because it describes less work.

Apply a batch-focused quality-control review

Define methods and acceptance criteria before purchase. HPLC commonly supports chromatographic purity and mass spectrometry can support identity, but neither should imply untested attributes. Check sample identifiers, dates, report numbers, units and lot relationships. Use the quality-control framework to connect each claim to evidence. Preserve original reports, record revisions and investigate contradictions before accepting the lot.

Create a documentation gate before dispatch

List the required COA, analytical attachments, SDS, specification, supported storage statement, label proof, invoice and packing list in the RFQ. Reconcile product, strength, lot, quantity and revision across documents using the documentation guide. The importer remains responsible for current destination rules. Research-use wording supports clarity but neither guarantees customs entry nor replaces destination-specific due diligence.

Qualify logistics and receiving controls

Confirm dispatch location, carrier, shipping term, packaging configuration and realistic production, release and transit windows. Reject promises of guaranteed clearance or misleading declarations. On receipt, record package condition, seals, product, strength, lot and quantity, then link internal inventory to the supplier batch. Quarantine unexplained discrepancies until a documented quality decision is completed.

Use actual performance for repeat-order approval

A controlled evaluation order should use the same specification planned for wholesale scale. Assess document accuracy, package condition, delivery time, communication and corrective response, and consider buyer-arranged testing appropriate to risk with documented sample custody. For every new lot, repeat the batch review. Require notification before changes to manufacturing, testing, filling, material specification, labels or packaging.

Related products and same-category guides

• Dihexa 5mg
• Dihexa 10mg
• PE-22-28 5mg
• PE-22-28 10mg
• Semax vs Selank Guide
• Third-Party Peptide Testing Guide

Frequently asked questions